New Opto Acoustic Focusing Technology Stabilizes Tiny Biological Samples
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Purdue University researchers have developed a new method to fixate bacteria, viruses, and complex molecules like DNA inside liquid droplets by using both electric fields and laser light.
Ordinarily, the particles inside droplets are detected when they randomly fall on a sensor's surface. However, the new method could improve sensor efficiency by actively moving particles to specific regions on an electronic chip for detection or analysis.
The method offers promise for future "lab-on-a-chip" technology, using electronic chips to analyze biological samples for medical and environmental applications.
Sensors based on the technique could make possible a new class of chemical analyzes, or assays, with point-of-care devices in a doctor's office or hospitals. Such sensors might be used to quickly analyze bodily fluids for a range of applications, including drug screening; paternity testing; detecting coronary artery disease, tumors and various inherited diseases including cystic fibrosis; and detecting infectious diseases and bacteria, viruses and fungi that are difficult to culture using conventional laboratory methods.
The mAb-Glyco-Chip is designed for the analysis of N-glycans associated with monoclonal antibody molecules. N-glycans and monoclonal antibody molecules are a critical part of biopharmaceutical research and analysis. A unique product for a specific requirement, the mAb-Glyco- Chip improves the productivity of biopharmaceutical analysis at least 20 times when compared to the current CE-FLD method, and at least five times when compared to the current MALDI-MS method.
Conventional methods of N-glycan analysis, such as LC-FLD or CE-FLD, can take two to three days for completing one single analysis. The new HPLC-Chip/MS workflow significantly reduces the total analysis (including on-chip enzymatic reaction, glycan separation and MS analysis) to tens of minutes. This creates a major productivity enhancement for biopharmaceutical analysis. Coupled with an Agilent Accurate Mass TOF or Q-TOF mass spectrometer, the combined system allows for complete, rapid characterization and quantitative profiling of glycan structures on recombinant antibodies.
The Agilent 1200 Series HPLC-Chip/MS system is a microfluidic chip-based technology for nanospray LC/MS. Agilent pioneered the HPLC-Chip/MS concept in 2005, combining nanoflow HPLC columns, and connecting capillaries and a spray emitter, into a reuseable, credit card-size device. This allowed the advantages of high-sensitivity and low-sample consumption provided by nano LC/MS to be accessible to scientists without the troublesome setup involving microvalve, fittings and capillary tubing of conventional nano LC. The mAb-Glyco-Chip will be available in September.
Ordinarily, the particles inside droplets are detected when they randomly fall on a sensor's surface. However, the new method could improve sensor efficiency by actively moving particles to specific regions on an electronic chip for detection or analysis.
The method offers promise for future "lab-on-a-chip" technology, using electronic chips to analyze biological samples for medical and environmental applications.
Sensors based on the technique could make possible a new class of chemical analyzes, or assays, with point-of-care devices in a doctor's office or hospitals. Such sensors might be used to quickly analyze bodily fluids for a range of applications, including drug screening; paternity testing; detecting coronary artery disease, tumors and various inherited diseases including cystic fibrosis; and detecting infectious diseases and bacteria, viruses and fungi that are difficult to culture using conventional laboratory methods.
The mAb-Glyco-Chip is designed for the analysis of N-glycans associated with monoclonal antibody molecules. N-glycans and monoclonal antibody molecules are a critical part of biopharmaceutical research and analysis. A unique product for a specific requirement, the mAb-Glyco- Chip improves the productivity of biopharmaceutical analysis at least 20 times when compared to the current CE-FLD method, and at least five times when compared to the current MALDI-MS method.
Conventional methods of N-glycan analysis, such as LC-FLD or CE-FLD, can take two to three days for completing one single analysis. The new HPLC-Chip/MS workflow significantly reduces the total analysis (including on-chip enzymatic reaction, glycan separation and MS analysis) to tens of minutes. This creates a major productivity enhancement for biopharmaceutical analysis. Coupled with an Agilent Accurate Mass TOF or Q-TOF mass spectrometer, the combined system allows for complete, rapid characterization and quantitative profiling of glycan structures on recombinant antibodies.
The Agilent 1200 Series HPLC-Chip/MS system is a microfluidic chip-based technology for nanospray LC/MS. Agilent pioneered the HPLC-Chip/MS concept in 2005, combining nanoflow HPLC columns, and connecting capillaries and a spray emitter, into a reuseable, credit card-size device. This allowed the advantages of high-sensitivity and low-sample consumption provided by nano LC/MS to be accessible to scientists without the troublesome setup involving microvalve, fittings and capillary tubing of conventional nano LC. The mAb-Glyco-Chip will be available in September.
